ALTEVAX

ALTEVAX develops an innovative and disruptive immunotherapy platform for the treatment of cancer. It is based on synthetic melanin, a non-toxic and versatile biopolymer adjuvant, that can be combined with a wide range of antigenic peptides for vaccine formulations. Melanin is a particularly powerful adjuvant inducing a specific immune response against the selected antigens that is more effective and faster than any current vaccine technology using emulsions, RNA or DNA as messenger vectors (proven in laboratory experiments). ALTEVAX lead program, a therapeutic vaccine against Glioblastoma, is based on the tumor-associated antigen TERT (from the telomerase complex). This tumor antigen has been successfully tested in phase 2 clinical trials (in combination with another adjuvant) with promising results in 2 different indications: Glioblastoma and Lung Cancer. The program is ready to go clinic with all necessary steps initiated. First patient is expected to be included in Q4 2024.